- EQRx’s low cost drug dream ends in Revolution FierceBiotech
- Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional Capital GlobeNewswire
- EQRx, failed developer of low-priced cancer drugs, is sold for cash STAT
- Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D MarketWatch
- Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital – EQ Benzinga
- View Full Coverage on Google News
Read More: EQRx’s low cost drug dream ends in Revolution – FierceBiotech